Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

Quick Read AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus by $280M, while Skyrizi surged 30.9% YoY to $4.48B ...

By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

AbbVie (ABBV) stock gains as the company raised its full-year earnings outlook despite a mixed performance in Q1 2026. Read ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...

AbbVie is scheduled to report Q1 earnings on April 29, before market open, with analysts expecting growth recovery both in ...

AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year, Reuters reports.

In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services Evernorth Health, a wholly owned subsidiary of Cigna ...

As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...